Notice of Award

Award# 1 NU17CE010204-01-00

FAIN# NU17CE010204

Federal Award Date: 08/23/2023

Recipient Information

1. Recipient Name

MISSOURI DEPARTMENT OF HEALTH & SENIOR SERVICES PO BOX 570

Jefferson Cty, MO 65102-0570

2. Congressional District of Recipient

- 3. Payment System Identifier (ID) 1446000987B7
- 4. Employer Identification Number (EIN) 446000987
- 5. Data Universal Numbering System (DUNS) 878092600
- 6. Recipient's Unique Entity Identifier (UEI) UETLXV8NG8F4
- 7. Project Director or Principal Investigator

Ms. LYNN SMITH LYNN.SMITH@HEALTH.MO.GOV 5735264862

8. Authorized Official

Ms. Marcia Mahaney Grants@health.mo.gov 573-751-6014

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Natasha Jones

Grants Management Officer

mgz2@cdc.gov

770-488-1649

10 Program Official Contact Information

Latoya Golden

Program Officer

qll1@cdc.gov

404.498.1726

Federal Award Information

11. Award Number

1 NU17CE010204-01-00

12. Unique Federal Award Identification Number (FAIN)

NU17CE010204

13. Statutory Authority

Section 311(c)(1) of the PHS Act (42 USC § 243(c)(1))

14. Federal Award Project Title

OVERDOSE DATA TO ACTION-STATES

15. Assistance Listing Number

93 136

16. Assistance Listing Program Title

Injury Prevention and Control Research and State and Community Based Programs

17. Award Action Type

18. Is the Award R&D?

	Summary Federal Award Financial Information			
19.	Budget Period Start Date 09/01/2023 - End Date 08/31/2024			
20.	Total Amount of Federal Funds Obligated by this Action	\$4,394,497.00		
	20a. Direct Cost Amount	\$4,186,091.00		
	20b. Indirect Cost Amount	\$208,406.00		
21.	Authorized Carryover	\$0.00		
22.	Offset	\$0.00		
23.	Total Amount of Federal Funds Obligated this budget period	\$0.00		
24.	Total Approved Cost Sharing or Matching, where applicable	\$0.00		
25.	Total Federal and Non-Federal Approved this Budget Period	\$4,394,497.00		
26.	Period of Perfomance Start Date 09/01/2023 - End Date 08/31/2028			
27.	Total Amount of the Federal Award including Approved Cost Sharing or Matching this Period of Performance	\$4,394,497.00		

28. Authorized Treatment of Program Income

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Ms. Tajsha LaShore

30. Remarks

Notice of Award

Award# 1 NU17CE010204-01-00

FAIN# NU17CE010204

Federal Award Date: 08/23/2023

Recipient Information

Recipient Name

MISSOURI DEPARTMENT OF HEALTH & SENIOR SERVICES

PO BOX 570

Jefferson Cty, MO 65102-0570

Congressional District of Recipient

03

Payment Account Number and Type

1446000987B7

Employer Identification Number (EIN) Data

446000987

Universal Numbering System (DUNS)

278002600

Recipient's Unique Entity Identifier (UEI)

UETLXV8NG8F4

31. Assistance Type

Cooperative Agreement

32. Type of Award

Other

I. Financial Assistance from the Federal Awarding Agency Only		
II. Total project costs including grant funds and all other financial participation		
a. Salaries and Wages	\$684,352.00	
b. Fringe Benefits	\$467,068.00	
c. TotalPersonnelCosts	\$1,151,420.00	
d. Equipment	\$0.00	
e. Supplies	\$27,331.00	
f. Travel	\$29,544.00	
g. Construction	\$0.00	

h. Other	\$294,834.00
i. Contractual	\$2,682,962.00
j. TOTAL DIRECT COSTS	\$4,186,091.00
k. INDIRECT COSTS	\$208,406.00

m. Federal Share \$4,394,497.00

n. Non-Federal Share \$0.00

34. Accounting Classification Codes

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	CFDA NO.	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
3-9390BX6	23NU17CE010204OPCE	CE	410Q	93.136	\$4,394,497.00	75-23-0952

1. TOTAL APPROVED BUDGET

33. Approved Budget

(Excludes Direct Assistance)

\$4,394,497.00



Award# 1 NU17CE010204-01-00

FAIN# NU17CE010204

Federal Award Date: 08/23/2023

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

MISSOURI DEPARTMENT OF HEALTH & SENIOR SERVICES

1 NU17CE010204-01-00

1. Terms and Conditions

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at https://www.cdc.gov/grants/federal-regulations-policies/index.html, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number CDC-RFA-CE-23-0002, entitled Overdose Data to Action in States, and application dated May 8, 2023, as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Approved Funding: Funding in the amount of \$4,394,497 is approved for the Year 01 budget period, which is September 1, 2023 through August 31, 2024. All future year funding will be based on satisfactory programmatic progress and the availability of funds.

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third-party in-kind contribution when applicable.

Note: Refer to the Payment Information section for Payment Management System (PMS) subaccount information.

Project/Component Funding: The NOFO provides for the funding of multiple components under this award. The approved component funding levels for this notice of award are:

NOFO Component	Amount
Surveillance	\$ 1,150,725
Surveillance Strategy 4	\$350,000
Prevention	\$ 2,893,772

Financial Assistance Mechanism: Cooperative Agreement

Substantial Involvement by CDC: This is a cooperative agreement and CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds.

CDC will provide substantial involvement beyond regular performance and financial monitoring during the period of performance. Substantial involvement means that recipients can expect federal programmatic partnership in carrying out the effort under the award. CDC's Division of Overdose Prevention (DOP), with support from the DOP Technical Assistance Center (TAC), will work in partnership with recipients to ensure the success of the cooperative agreement by:

- Assisting in advancing program activities to achieve project outcomes
- Providing technical assistance on data management plans
- Collaborating with recipients to develop evaluation plans that align with CDC evaluation activities.
- Providing technical assistance on the recipient's Evaluation and Performance

Measurement Plan

- Providing technical assistance on recipient's Targeted Evaluation Project
- Providing technical assistance to define and operationalize performance measures
- Facilitating the sharing of information among recipients
- Participating in relevant meetings, committees, conference calls, and working groups related to - the cooperative agreement requirements
- Coordinating communication and program linkages with other CDC programs and Federal agencies, such as the Centers for Medicare and Medicaid Services (CMS), Food and Drug Administration (FDA), the National Institutes of Health (NIH), Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Justice (DOJ), and the HHS Office of the National Coordinator for Health Information Technology (ONC)
- Translating and disseminating lessons learned and best practices through publications, reports, technical packages, meetings, and other means to expand the evidence base; and
- Identifying and awarding a partner organization to expand and strengthen recipients' capacity to implement surveillance and prevention activities through jurisdiction-level staffing support.

Additionally, technical assistance around the funding announcement's guiding principles (see Logic Model) will be available to ensure that all recipients are able to:

- Collect data around community and demographic characteristics, including race and ethnicity, and conduct analyses that consider social determinants of health and use a health equity lens
- Use data to inform and tailor prevention programs, with emphasis on reaching groups disproportionately affected by the overdose epidemic; and
- Ensure implementation of culturally relevant interventions and equitable delivery of prevention services.

The TAC will leverage various modes of technical assistance, including group training, webinars, communities of practice, individualized one-on-one assistance, peer-to-peer interactions, and asynchronous learning to increase recipient capacity to implement evidence-based interventions and successfully execute NOFO strategies. DOP staff and DOP TAC subject matter experts will work with the recipients to provide scientific subject matter expertise and resources by:

- Providing cross-site and recipient-specific surveillance technical assistance, such as
 providing tools to identify nonfatal overdoses using standardized discharge diagnosis
 coding (i.e., ICD-10-CM) and unstandardized free text (e.g., chief complaint)
- Providing cross-site and recipient-specific surveillance technical assistance, such as
 providing tools to identify fatal drug poisonings using ICD-10 cause of death codes and
 free text from the medical examiner and coroner reports
- Providing guidance on SUDORS data abstraction, use of necessary data sharing platforms (e.g., NVDRS, NSSP ESSENCE), and CDC processes to collect required nonfatal data
- Supporting the use of CDC's nonfatal overdose case definitions by providing recipients computer programming code such as SAS, R, and ESSENCE to implement the cases definitions if resources are available

- Providing ongoing data quality reviews and feedback on required nonfatal and fatal overdose data submissions
- Providing guidance and technical assistance for Bio surveillance and Data Linkage projects to jurisdictions funded through the respective optional and competitive surveillance strategies
- Coordinating health information technology and prescription drug monitoring program (PDMP) communication, program linkages, and technical assistance (TA) with other CDC programs, TA providers, and federal agencies, such as the Bureau of Justice Assistance (BJA), the HHS Office of the National Coordinator for Health Information Technology (ONC), and the PDMP Training and Technical Assistance Center (TTAC); and
- Providing guidance on using data to inform jurisdiction-level populations of focus, with a health equity lens, selecting evidence-based overdose prevention interventions, and implementing best practices across all four prevention strategies.

Expanded Authority: The recipient is permitted the following expanded authority in the administration of the award.

☑ Carryover of unobligated balances from one budget period to a subsequent budget period. Unobligated funds may be used for purposes within the scope of the project as originally approved. Recipients will report use, or intended use, of unobligated funds in Section 12 "Remarks" of the annual Federal Financial Report. If the GMO determines that some or all of the unobligated funds are not necessary to complete the project, the GMO may restrict the recipient's authority to automatically carry over unobligated balances in the future, use the balance to reduce or offset CDC funding for a subsequent budget period, or use a combination of these actions.

FUNDING RESTRICTIONS AND LIMITATIONS

Indirect Costs: Indirect costs are approved based on the negotiated indirect cost rate agreement dated March 16, 2022, which calculates indirect costs as follows: a Provisional is approved at a rate of 18.1% of the base, which includes direct salaries and wages including all fringe benefits. The effective dates of this indirect cost rate are from July 1, 2023 to June 30, 2025.

Missing Contractual Elements – The contracts below are **not** approved, and the recipient may not begin the contracts until contractor names and itemized budgets with justification are provided via GrantSolutions as a notification of contractor amendment and GMO approval is provided via Notice of Award.

Evaluation contract (surveillance)
Harm Reduction Contractors
Harm Reduction campaign
Harm Reduction conference- also provide period of performance
Local Public Health Agencies (LPHA) contracts
Evaluation contract
Transportation Program Contractor
Clinical Educator
Naloxone Distribution and Tracking

REPORTING REQUIREMENTS

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services
Natasha Jones, Grants Management Officer/Specialist
Centers for Disease Control and Prevention
Branch 5 Supporting Chronic Diseases and Injury Prevention
2960 Brandywine Road
Atlanta, Georgia 30341
Email: mgz2@cdc.gov (Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services
Office of the Inspector General
ATTN: Mandatory Grant Disclosures, Intake Coordinator
330 Independence Avenue, SW
Cohen Building, Room 5527
Washington, DC 20201

Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or

Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified beginning on the bottom of Page 2 of the Notice of Award must be known in order to draw down funds.